Sarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total value of $1,167,000.00. Following the transaction, the insider now directly owns 1,098,499 shares in the company, valued at approximately $12,819,483.33. This trade represents a 8.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, December 10th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.16, for a total value of $1,316,000.00.
• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY opened at $11.18 on Friday. The company has a fifty day moving average price of $14.44 and a 200-day moving average price of $12.42. ARS Pharmaceuticals, Inc. has a 1 year low of $5.02 and a 1 year high of $18.51. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -21.92 and a beta of 0.88.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SPRY. nVerses Capital LLC bought a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after acquiring an additional 4,472 shares during the period. Principal Financial Group Inc. bought a new stake in ARS Pharmaceuticals during the second quarter worth $87,000. J.W. Cole Advisors Inc. boosted its position in ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Quarry LP bought a new position in ARS Pharmaceuticals in the 3rd quarter valued at $174,000. 68.16% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Finally, Leerink Partners lifted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $24.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.